Onyx Biotec logo

Onyx Biotec

ONYX NSE
₹37.00 1.00 (2.63%)
Market Cap
₹67.09 Cr

Key Fundamentals

SMEPharmaceuticalsHealthcare
Market Cap
₹67.09 Cr
EBITDA
₹3.80 Cr
Return on Equity
-0.39%
Debt to Equity
0.27
Book Value
₹30.56
EPS (TTM)
—
52W High
₹49.65
52W Low
₹24.20

Price-based figures as of 13 Oct 2026, 13:14 IST · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,770.7035.134,24,850 Cr5.080.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,285.0084.272,46,488 Cr14.710.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,642.9072.891,76,601 Cr21.000.82%12.16%9.06%15,391 Cr2,156 Cr
Zydus Life Science
₹1,132.5025.201,12,967 Cr4.170.09%16.99%19.24%28,515 Cr4,593 Cr
Laurus Labs
₹2,059.40101.751,11,272 Cr21.000.10%16.38%19.67%7,323 Cr1,090 Cr
Cipla
₹1,329.6031.851,07,413 Cr3.121.00%11.21%14.88%28,786 Cr3,356 Cr
Dr Reddys Laboratories
₹1,240.0032.121,03,500 Cr2.720.67%10.87%13.94%34,555 Cr3,184 Cr
Mankind Pharma
₹2,372.0047.9597,974 Cr6.010.04%11.70%13.78%15,074 Cr2,067 Cr
Aurobindo Pharma
₹1,684.6026.2896,928 Cr2.560.24%9.25%13.58%35,390 Cr3,711 Cr
Lupin
₹1,953.6016.1589,336 Cr3.980.92%23.79%28.42%30,017 Cr5,552 Cr
Onyx Biotec (this company)
₹37.00—67 Cr1.210.00%-0.39%1.26%——
Median 11 companies₹1,770.7033.631,07,413 Cr4.170.32%12.16%14.88%28,651 Cr3,270 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-12
v2.0.0
46 Average
Overall score
Data confidence 81/100
surveillance:ESM1

Category scores

Quality Poor 28
Returns, margins, earnings quality 22%
Valuation Weak 43
Cheap vs sector & own history 24%
Growth Average 54
Sales & profit trajectory 9%
Financial Health Poor 33
Solvency, leverage, coverage 9%
Momentum Strong 70
Trend strength, vol-adjusted 12%
Ownership Strong 73
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

2
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 6.12% over last 3 years.

Technical Indicators

Oscillators

BearishNeutralBullish

Bullish

Bearish
0
Neutral
7
Bullish
2

Overall

BearishNeutralBullish

Neutral

Bearish
6
Neutral
7
Bullish
6

Moving Averages

BearishNeutralBullish

Bearish

Bearish
6
Neutral
0
Bullish
4

Growth Rate

Revenue Growth
10.78% lower than 3Y

change over 1 year

Net Income Growth
-104% higher than 3Y

change over 1 year

Cash Flow Change
-205%

change over 1 year

EBITDA Margin Change
-69.9%

change over 1 year Operating margin 7.02% · Mar 2026

Quarterly Results

Particulars Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
23.89
29.86
30.15
31.8
34.59
34.88
Expenses
20.47
24.95
24.44
27.17
33.65
32.43
Operating Profit
3.42
4.91
5.71
4.63
0.94
2.45
OPM %
14.32%
16.44%
18.94%
14.56%
2.72%
7.02%
Other Income
0.04
0.09
0.99
0.18
0.24
0.21
Interest
0.83
1.27
1.36
0.62
0.55
0.66
Depreciation
0.73
1.14
1.53
1.51
1.56
1.49
PBT
1.9
2.59
3.81
2.68
-0.93
0.51
Tax %
15.26%
21.24%
21.52%
26.12%
-3.23%
-35.29%
Net Profit
1.6
2.03
2.99
1.97
-0.9
0.69
EPS (₹)
2.71
1.52
2.24
1.09
-0.5
0.38
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
44.86
39.49
53.75
61.95
69.47
Expenses
39.09
34.99
45.36
51.57
66.06
Operating Profit
5.77
4.5
8.39
10.38
3.41
OPM %
12.86%
11.4%
15.61%
16.76%
4.91%
Other Income
0.12
0.11
0.13
1.17
0.44
Interest
0.65
0.57
2.16
2.02
1.22
Depreciation
1.45
1.49
1.87
3.05
3.05
PBT
3.79
2.55
4.49
6.48
-0.42
Tax %
11.61%
27.45%
19.15%
23.46%
-50%
Net Profit
3.35
1.84
3.63
4.95
-0.21
EPS (₹)
5.68
3.12
2.72
2.73
-0.12
Div. Payout %
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5.9
5.9
13.32
18.13
18.13
Reserves
10.47
12.3
11.97
37.49
37.28
Borrowings
12.25
29.23
30.78
12.46
15.17
Other Liabilities
8.22
11.3
18.07
23.17
24.58
Total Liabilities
36.84
58.73
74.14
91.25
95.16
Fixed Assets
17.23
42.5
43.48
40.9
39.16
CWIP
4.02
0
0
0
3.68
Investments
0
0
0
0
0
Other Assets
15.59
16.23
30.66
50.35
52.32
Total Assets
36.84
58.73
74.14
91.25
95.16
Figures in ₹ Crores

Cash Flow

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.49
1.96
1.52
1.42
-1.49
Investing
-5.78
-22.68
-3.15
0.66
-4.58
Financing
5.2
16.43
3.09
5.07
1.5
Net Cash Flow
-0.09
-4.3
1.46
7.15
-4.57
Free Cash Flow
-5.3
-20.78
-1.7
1.91
-6.48
CFO/OP
8
44
18
14
-44
Figures in ₹ Crores

Ratios

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68.51
46.95
104
119
144
Inventory Days
41.98
110
92.94
150
99.2
Days Payable
59.46
120
141
156
125
Cash Conversion Cycle
51.03
36.71
56.48
113
119
Working Capital Days
35.72
-52.22
37.62
87.49
77.29
ROCE %
—
8.23%
12.85%
12.16%
1.15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Onyx Biotec insights

51 extracted metrics + investor summaries across FY22–FY26.

Log in — free

Shareholding Pattern

FIIs1.07%Promot.65.10%DIIs2.39%Others8.29%Public23.15%As ofMar 2026

Documents

Frequently Asked Questions about Onyx Biotec

What does Onyx Biotec Ltd do?
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model[1]
Where is Onyx Biotec Ltd (ONYX) listed?
Onyx Biotec Ltd trades as ONYX on the NSE.
Which sector does Onyx Biotec Ltd belong to?
Onyx Biotec Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Onyx Biotec Ltd?
Onyx Biotec Ltd has a market capitalisation of ₹67.09 Cr as of 13 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Onyx Biotec Ltd?
Over the last 52 weeks Onyx Biotec Ltd has traded between ₹24.2 and ₹49.65 as of 13 Oct 2026.
What is the Return on Equity (ROE) of Onyx Biotec Ltd?
Onyx Biotec Ltd reported a return on equity of -0.39%. Its debt-to-equity ratio is 0.27.

Company Information

Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model[1]

Website onyxbiotec.com
Listed 2024-11-22
Face Value ₹ 10
Shares Outstanding 1,81,32,200

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ONYX.md for Onyx Biotec Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List